Positive modulators of the AMPA receptor

Bibliography

• MONAGHAN DT, YAO D, COTMAN CW: Distribution of [311]AMPA binding sites in rat brain as determined by quantitative autoradiography. Brain Research (1984) 324:160–164.
   PubMed Web of Science ®Google Scholar
• ARAI A, LYNCH G: Factors regulating the magnitude of long-term potentiation induced by theta pattern stimulation. Brain Research (1992) 598:173–184.
   PubMed Web of Science ®Google Scholar
• GRANGER R, STAUBLI U, DAVIS M et al.: Adrug that facili-tates glutamatergic transmission reduces exploratory activity and improves performance in a learned-dependant task. Synapse (1993) 15:326–329.
   PubMed Web of Science ®Google Scholar
• STAUBLI U, ROGERS G, LYNCH G: Facilitation of glutamate receptors enhances memory. Proc. Natl. Acad. ScL USA (1994) 91:777–781.
   PubMed Web of Science ®Google Scholar
• ARAI A, KESSLER M, XIAO P, AMBROS-INGERSON J, ROGERS G, LYNCH G: A centrally active drug that modulates AMPA receptor gated currents. Brain Res. (1994) 638:343–346.
   PubMed Web of Science ®Google Scholar
• STAUBLI U, PEREZ Y, XU FB et al: Centally active modulators of glutamate receptors facilitate the induction of long-term potentiation in viva Proc. Natl. Acad. ScL USA (1994) 91:11158–11162.
   PubMed Web of Science ®Google Scholar
• SHORS TJ, SERVATIUS RJ, THOMPSON RF, ROGERS G, LYNCH G: Enhanced glutamatergic neurotransmission facilitates classical conditioning in the freely moving rat. Neurosci. Lett. (1995) 186:153–156.
   PubMed Web of Science ®Google Scholar
• LARSON J, LIEU T, PETCHPRADUB V et al: Facilitation of ofactory learning by a modulator of AMPA recep tors. J. Neurosci. (1995) 15:8023–8030.
   PubMed Web of Science ®Google Scholar
• GRANGER R, DEADWYLER S, DAVIS M et al: Facilitation of glutamate receptors reverses an age-associated memory impairment in rats. Synapse (1996) 22:332–337.
   PubMed Web of Science ®Google Scholar
• ARAI A, KESSLER M, ROGERS G, LYNCH G: Effects of a memory enhancing drug on DL-(0C-amino-3-hydroxy-5-methy1-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus. J. Pharmacol. Exp. Ther. (1996) 278:627–638.
   PubMed Web of Science ®Google Scholar
• LYNCH G, KESSLER M, ROGERS G, AMBROS-INGERSON J, GRANGER R, SCHEHR RS: Psychological effects of a drug that facilitates brain AMPA receptors. Internal-I. Olin. Psychopharm. (1996) 11:13–19.
   PubMed Web of Science ®Google Scholar
• LYNCH G, GRANGER R, AMBROS-INGERSON J, DAVIS CM, KESSLER M, SCHEHR R: Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp. Neurology (1997) 145:89–92.
   PubMed Web of Science ®Google Scholar
• •A report on the use of the ampakine CX516 in humans.
   Google Scholar
• INGVAR M, AMBROS-INGERSON J, DAVIS M et al.: Enhancement by an ampakine of memory encodingin humans. Exp. Neurology (1997) 146:553–559.
   PubMed Web of Science ®Google Scholar
• HAMPSON RE, ROGERS G, LYNCH G DEADWYLER SA: Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J Neurosci. (1998) 18:2748–2763.
   PubMed Web of Science ®Google Scholar
• DEL CERRO, JUNG M, LYNCH G: Benzodiazepines block long-term potentiation in slices of hippocampus and piriform cortex. Neuroscience (1992) 49:1–6.
   PubMed Web of Science ®Google Scholar
• ANDREASEN NC, O'LEARY DS, FLAUM M et al: Hypofron-tality in schizophrenia: distributed dysfunctional circuits in neurolep tic-naive patients. Lancet (1997) 349:1730–1734.
   PubMed Web of Science ®Google Scholar
• WEINBERGER DR, BERMAN KF: Prefrontal function in schizophrenia: confounds and controversies. Philos. Trans. R. Soc. Lond. B. Biol. ScL (1996) 351:1495–1503.
   PubMed Web of Science ®Google Scholar
• WEINBERGER DR, LIPSKA BK: Cortical maldevelop-ment, anti-psychotic drugs and schizophrenia: a search for common ground. Schizophrenia Res. (1995) 16:87–110.
   PubMed Web of Science ®Google Scholar
• EASTVVOOD SL, KERWIN RW, HARRISON PJ: Irnmunoau-toradiographic evidence for a loss of a-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol. Psychiatry (1997) 41:636–643.
   PubMed Web of Science ®Google Scholar
• BREESE CR, FREEDMAN R, LEONARD SS: Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. (1995) 674:82–90.
   PubMed Web of Science ®Google Scholar
• EASTVVOOD SL, MCDONALD B, BURNET PW, BECKWITH JP, KERWIN RW, HARRISON PJ: Decreased expression of mRNAs encoding non-NMDA glutamate receptors G1uR1 and G1uR2 in medial temporal lobe neurons in schizophrenia. Mot. Brain Res. (1995) 29:211–223.
   Web of Science ®Google Scholar
• EASTWOOD SL, BURNET PW, HARRISON PJ: G1uR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizo-phrenia: a reverse transcriptase-polymerase chain reaction (RT-PCR) study. Mot. Brain Res. (1997) 44:92–98.
   Web of Science ®Google Scholar
• KIM JS, KORNHUBER HH, SCHMID-BURGK W, HOLZMUELLER B: low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. (1980) 20:379–382.
   PubMed Web of Science ®Google Scholar
• TSAI G, PASSANI LA, SLUSHER BS et al: Abnormal excita-tory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry (1995) 52:829–836.
   PubMed Web of Science ®Google Scholar
• FREED WJ, WEINBERGER DR, BING LA, WYATT RJ: Neuropharmacological studies of phencyclidine (PCP)-induced behavioral stimulation in mice. Psycho-pharmacology (1980) 71:291–297.
   PubMed Web of Science ®Google Scholar
• LAHTI AC, KOFFEL B, LAPORTE D, TAMMINGA CA: Sub anaesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology (1995) 13:9–19.
   PubMed Web of Science ®Google Scholar
• KRYSTAL JH, KARPER LP, SEIBYL JP et al.: Subanaesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch. Gen. Psychiatry (1994) 51:199–214.
   Google Scholar
• GOFF DC et al., submitted for publication (personal communication to Gary Rogers).
   Google Scholar
• ITO I, TANABE S, KOHDA A, SUGIYAMA H: Mlosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. j Physiol. (1990) 424:533–543.
   PubMed Web of Science ®Google Scholar
• STAUBLI U, KESSLER M, LYNCH G: Aniracetam has proportionately small effects on synapses expressing long-term potentiation: evidence that receptor changes subserve LTP. Psychobiology (1990) 18:377–381.
   Google Scholar
• XIAO P, STAUBLI U, KESSLER M, LYNCH G: Selective effects of aniracetam across receptor types and forms of synaptic facilitation in hippocampus. Hippocampus (1991) 1:73–80.
   Google Scholar
• GUENZI A, ZANETTI M: Determination of aniracetamand its main metabolite, N-anisoyl-GABA, in human plasma by high-performance liquid chromatography. Chromatogr. (1990) 530:397–406.
   Google Scholar
• YAMADA KA, ROTHMAN SM: Diazoxide blocks glutamate desensitization and prolongs excitatory postsynaptic currents in rat hippocampal neurones. J. Physiol. (1992) 458:385–407.
   PubMed Web of Science ®Google Scholar
• YAMADA KA: Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease. Exp. Opin. Invest. Drugs (2000) 9:765–777.
   PubMed Web of Science ®Google Scholar
• ••An excellent review on AMPA receptor positive modulators.
   Google Scholar
• YAMADA KA: Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease? Neurobiol Dis. (1998) 5:67–80.
   Google Scholar
• ZIMMERMAN, DM: Structurally novel AMPA potentia-tors: new opportunities for drug development. 219th ACS National Meeting San Francisco, CA, USA, (26–30 March, 2000).
   Google Scholar
• ••Presentation outlining the progress Lilly have made and theSAR around a novel class of AMPA receptor potentiators.
   Google Scholar
• DESOS P, SERKIZ B, MORAIN P, LEPAGNOL J, CORDI A: Enantioselective synthesis of a pyrrolobenzothiadi-azine derivative S 18986, a new AMPAreceptor positive modulator. Bioorg. Med. Chem. Lett. (1996) 6:3003–3008.
   Google Scholar
• PIROTTE B, PODONA T, DIOUF O et al.: 4H-1,2,4-pyrido thiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2,4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/5)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors: design, synthesis, pharmacology and structure-activity relationships. J. Med. Chem. (1998) 41:2946–2959.
   PubMed Web of Science ®Google Scholar
• •The SAR around the thiazide class of compounds.
   Google Scholar
• SEKIGUCHI M, FLECK MW, MAYER ML et al.: A novel allosteric potentiator of AMPA recep tors: 442-(phenyl-sulfo n ylam in o)ethylthio]-2,6 -difluor o -p hen oxy acetamide. j Neurosci. (1997) 17:5760–5771.
   PubMed Web of Science ®Google Scholar